Medipost (078160) has recruited Min Ho-sung, former vice president and head of the CDMO Development Center at Samsung Biologics, as president to lead its global expansion. The company plans to appoint him CEO through an extraordinary shareholders' meeting and board resolution, creating a co-CEO structure with current CEO Oh Won-il; Min will also become chairman of the board. Oh will oversee domestic operations, while Min will lead the Global Business Division, U.S. and Japan subsidiaries, OmniaBio, overseas clinical trials and business development across North America, Europe and China. The appointment comes as Medipost prepares to commercialize Cartistem, its stem cell-based osteoarthritis treatment, overseas. Cartistem's Phase 3 trial in Japan met both primary and secondary endpoints, and Medipost is preparing a Biologics License Application. Its U.S. Phase 3 trial has begun patient dosing under a Single Study approach expected to cut costs by approximately 20–30% and shorten the timeline by 3–6 months, with total clinical development expected to take approximately 42–45 months.